Chippenham,
In
Award of
Ongoing royalties of 3% on US sales of certain infringing GSK Ellipta® products
Supplemental damages based on GSK's infringing sales of approximately
Pre-judgment interest at the prime rate of approximately
GSK has 30 days to file a petition for rehearing.
Background to litigation
In
Vectura and GSK had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family. These licensed patents expired in
From the outset, Vectura has been open to finding a mutually acceptable solution to avoid prolonging the dispute. However, the litigation progressed to a jury trial in
As reported in
Amounts received will be subject to taxation in the
- Ends-
+44 (0)20 3709 5700
About Vectura
Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has eleven key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include
For further information, please visit Vectura's website at www.vectura.com
Forward-looking statements
This press release contains forward-looking statements, including statements about the commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward looking statements, including: commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
.
(C) 2020 M2 COMMUNICATIONS, source